Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triethylene Glycol SCHEMBL29103842 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL24748 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL607716 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL16437096 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL599527 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL607698 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL12865302 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL16437099 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL606328 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 | |
| SCHEMBL851320 | 1.00 | TSHR (0.58) | TSHRNAAAKDM4EPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4129345-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | disclosed |
| WO-2005117985-A2 | LIPOPOLYPLEX CONSTRUCT WITH AN INTEGRIN BINDING PEPTIDE FOR DELIVERY OF NUCLEIC ACIDS, PEPTIDES OR DRUGS | UCL BIOMEDICA PLC (GB) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | NANOGENICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | ITGB1, ITGA2B, ITGB2 | TSHR 616/4885NAAA 4315/4885KDM4E 4564/4885 |
| US-20230165969-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY DRUG CONJUGATE AND USE THEREOF | CFD, DDOST, HEXD | TSHR 2692/4885NAAA 3139/4885KDM4E 1344/4885 |
| US-20230241242-A1 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | FCGR1A, FCGR3B, FCGR2A | TSHR 904/4885NAAA 801/4885KDM4E 2996/4885 |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | NQO1, NR5A1, SRD5A1 | TSHR 4285/4885NAAA 1886/4885KDM4E 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.